Yoshida Noboru, Okumura Ki-ichi, Aso Yoshimasa
Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama 343-8555, Japan.
Metabolism. 2005 Mar;54(3):345-50. doi: 10.1016/j.metabol.2004.09.014.
Accumulation of advanced glycation end products in vessel walls may increase arterial stiffness and/or thickness, contributing to a high incidence of cardiovascular disease (CVD) in patients with diabetes. We investigated whether serum concentrations of pentosidine, a well-defined advanced glycation end product, are associated with arterial stiffness or thickness in patients with type 2 diabetes. Pentosidine was measured in sera from 98 patients with type 2 diabetes and 61 age-matched control subjects by a competitive enzyme-linked immunosorbent assay. Arterial stiffness was evaluated by heart-brachial and brachial-ankle pulse wave velocities (PWVs) measured using an automatic device. Arterial thickness was determined ultrasonographically as carotid intima-media wall thickness (IMT). Serum concentrations of pentosidine were significantly higher in patients with diabetes than in control subjects (64.4 +/- 21.0 vs 22.8 +/- 7.0 microg/L; P < .0001). In patients with diabetes, serum pentosidine correlated positively with heart-brachial PWV (r = 0.304; P < .01) but not with brachial-ankle PWV. Serum pentosidine also correlated positively with carotid IMT in patients with diabetes (r = 0.300; P < .01). Serum pentosidine concentrations were significantly higher in patients with diabetes with CVD than in those without (72.3 +/- 23.7 vs 62.3 +/- 19.8 microg/L; P = .0453). By multivariate analysis, only age (partial coefficient = 0.308; P < .05) and serum creatinine (partial coefficient = 0.328; P < .01) retained significant influence on serum pentosidine. After adjustment for renal function, carotid IMT still correlated positively with serum pentosidine (partial coefficient = 0.2736; P = .021). In conclusion, serum pentosidine was positively associated with both arterial stiffness and thickness and CVD in patients with type 2 diabetes.
血管壁中晚期糖基化终末产物的积累可能会增加动脉僵硬度和/或厚度，导致糖尿病患者心血管疾病（CVD）的高发病率。我们研究了血清中已明确的晚期糖基化终末产物戊糖苷的浓度是否与2型糖尿病患者的动脉僵硬度或厚度相关。采用竞争性酶联免疫吸附测定法，对98例2型糖尿病患者和61例年龄匹配的对照者的血清进行戊糖苷检测。通过使用自动装置测量心臂和臂踝脉搏波速度（PWV）来评估动脉僵硬度。通过超声检查确定动脉厚度为颈动脉内膜中层厚度（IMT）。糖尿病患者血清戊糖苷浓度显著高于对照组（64.4±21.0 vs 22.8±7.0μg/L；P <.0001）。在糖尿病患者中，血清戊糖苷与心臂PWV呈正相关（r = 0.304；P <.01），但与臂踝PWV无关。血清戊糖苷在糖尿病患者中也与颈动脉IMT呈正相关（r = 0.300；P <.01）。患有CVD的糖尿病患者血清戊糖苷浓度显著高于未患CVD的患者（72.3±23.7 vs 62.3±19.8μg/L；P =.0453）。通过多变量分析，只有年龄（偏回归系数 = 0.308；P <.05）和血清肌酐（偏回归系数 = 0.328；P <.01）对血清戊糖苷仍有显著影响。在调整肾功能后，颈动脉IMT仍与血清戊糖苷呈正相关（偏回归系数 = 0.2736；P =.021）。总之，血清戊糖苷与2型糖尿病患者的动脉僵硬度、厚度以及CVD均呈正相关。
